1.Participants who received any other SARS-CoV-2 vaccine (except for the specified mRNA vaccine) or other experimental novel coronavirus vaccine prior to the trial.2.Participant who received a booster vaccination (i.e. 3rd dose) 3.Participants who have close contact of anyone known to have COVID-19 within 14 days prior to the trial vaccination.4.Participants who were tested positive for SARS-CoV-2 prior to the trial.5.Participants who have traveled outside of Japan in the 30 days prior to the trial participation.6.Participants with a clinically significant active infection or oral temperature >= 38 degree Celsius within 3 days of the intended date of vaccination.7.Participants with body mass index (BMI) greater than or equal to 30 kg/m^2 (BMI= weight in kg/ height in meters^2).

1.Participants who received any other SARS-CoV-2 vaccine (except for the specified mRNA vaccine) or other experimental novel coronavirus vaccine prior to the trial.2.Participant who received a booster vaccination (i.e. 3rd dose) 3.Participants who have close contact of anyone known to have COVID-19 within 14 days prior to the trial vaccination.4.Participants who were tested positive for SARS-CoV-2 prior to the trial.5.Participants who have traveled outside of Japan in the 30 days prior to the trial participation.6.Participants with a clinically significant active infection or oral temperature >= 38 degree Celsius within 3 days of the intended date of vaccination.7.Participants with body mass index (BMI) greater than or equal to 30 kg/m^2 (BMI= weight in kg/ height in meters^2).